Genentech Joins Hunt For ‘Molecular Glue’ Drugs With Orionis
Will Aim At ‘Undruggable’ Oncology and Neurodegeneration Targets
Genentech is broadening its stake in the protein degradation field, following BMS and Merck & Co into molecular glue drugs.
You may also be interested in...
Plus deals involving Debiopharm/SunRock, RefleXion/3B Pharmaceuticals, Pharmanovia/Sanofi and more.
RayzeBio's IPO and Genentech's first buy-in into the field show a wave of next-generation companies hoping to expand the radiopharmaceutical field.
The Swiss pharma sees the acquisition as the ‘backbone’ for its future cardiometabolic portfolio, which could include a combination with a muscle-building therapy.